Headquartered in Audubon, PA Fiscal year ends December NYSE: GMED globusmedical.com
Globus Medical, Inc. is a global musculoskeletal technology company that develops and commercializes solutions across spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. The company operates through two primary product categories: Musculoskeletal Solutions, which encompasses its spine, trauma, and joint reconstruction implant portfolios, and Enabling Technologies, which includes robotic-assisted surgery and navigation systems. In 2025, Globus acquired Nevro Corp., expanding its portfolio into spinal cord stimulation and pain management therapies. The company utilizes an exclusive selling model and emphasizes a closed-loop surgical intelligence ecosystem that integrates patient selection, surgical techniques, complementary implants, and technology platforms to improve surgical outcomes. Globus serves surgeons and healthcare facilities globally, with approximately 78% of revenue generated in the United States and the remainder from international markets. Updated
Shares of Affirm Holdings (NASDAQ: AFRM | AFRM Price Prediction) are up about 9%, or by $5.88 on the day. All thanks to solid earnings. EPS of 23 cents beat estimates by…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Wednesday's top analyst upgrades and downgrades included Arm, Carnival, CVS Health, Deere, Dell Technologies, Intercontinental Exchange, Planet Fitness, Rackspace Technology, Royal Caribbean Cruises, SoFi Technologies, Southwest Airlines, Starbucks and Super Micro Computer.
Tuesday's top analyst upgrades and downgrades included Agilon Health, Boston Scientific, General Motors, JPMorgan Chase, Match, Moderna, Okta, Palo Alto Networks, Snap, Uber Technologies and Wells Fargo.
Friday's top analyst upgrades and downgrades included American Tower, Charles Schwab, Crown Castle, DiamondRock Hospitality, DraftKings, Enphase Energy, GitLab, Interpublic Group of Companies, Juniper Networks, Philip Morris International, Shoals Technologies and Sunrun.
Monday's top analyst upgrades and downgrades included AbbVie, Affirm, Bloom Energy, FREYR Battery, International Flavors & Fragrances, Interpublic Group of Companies, Lyft, Micron Technology, Nutrien, Seagate Technology, Tapestry, VFC, Walmart and Western…
Monday's top analyst upgrades and downgrades included Advanced Micro Devices, Danaher, DoorDash, Freeport-McMoRan, Gap, Gilead Sciences, Huntington Bancshares, Independence Realty Trust, Intuitive Surgical, KeyCorp, Marvell Technology, McDonald's, Medical Properties Trust, Nucor, PayPal,…
Tuesday's top analyst upgrades and downgrades included Apple, Beyond Meat, Chesapeake Energy, Chewy, CrowdStrike, DraftKings, Qualtrics International, SAP, Sono, Tata Motors and Unity Software.
Credit Suisse has assembled its favorite health care recovery stocks for a recovering base of elective surgeries and for the risk of rising hospitalizations that go well beyond COVID-19.
It's another day that the markets are open, so it is widely assumed that Warren Buffett and his Berkshire Hathaway are out looking for deals to make.
A Credit Suisse analyst issued a broad new sector coverage for medical devices and related companies with strong Outperform ratings on Tuesday.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Albermarle, Boston Scientific, BP, Embraer, Intuit, Marathon Oil and Norfolk Southern.
The top analyst upgrades, downgrades and other research calls from Friday include AMD, CVS Health, Disney, Fiat Chrysler, Kinross Gold, Kohl's and NVIDIA.
Thinkstock24/7 Wall St. has tracked nine key stocks on the move in the after-hours trading session on Tuesday, August 5, 2014. There will have been other movers as well, but these were…
Here are four top medical device makers that the Leerink team thinks make sense as potential takeover candidates, but also have more than enough merit to stand on their own.
Globus Medical, Inc. is a global musculoskeletal technology company that develops and commercializes solutions across spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
24/7 Wall St.'s 12-month price target for GMED is $97.71, rated Buy. The Wall Street consensus target is $100.92. GMED price prediction →
